Compile Data Set for Download or QSAR
Report error Found 229 Enz. Inhib. hit(s) with all data for entry = 3447
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400703BDBM400703(US10000476, Compound I-62)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400699BDBM400699(US10000476, Compound I-64 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400698BDBM400698(US10000476, Compound I-57)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400699BDBM400699(US10000476, Compound I-64 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400700BDBM400700(US10000476, Compound I-59)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400231BDBM400231(US10000476, Compound I-1 | US10000476, Compound I-...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400697BDBM400697(US10000476, Compound I-56)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400690BDBM400690(US10000476, Compound I-49)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400691BDBM400691(US10000476, Compound I-50)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400692BDBM400692(US10000476, Compound I-51)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400693BDBM400693(US10000476, Compound I-52)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400718BDBM400718(US10000476, Compound I-77)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400719BDBM400719(US10000476, Compound I-78)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400720BDBM400720(US10000476, Compound I-79)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400721BDBM400721(US10000476, Compound I-80)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400714BDBM400714(US10000476, Compound I-73)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400715BDBM400715(US10000476, Compound I-74)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400716BDBM400716(US10000476, Compound I-75)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400710BDBM400710(US10000476, Compound I-69)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400712BDBM400712(US10000476, Compound I-71)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400713BDBM400713(US10000476, Compound I-72)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400706BDBM400706(US10000476, Compound I-65)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400707BDBM400707(US10000476, Compound I-66)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400708BDBM400708(US10000476, Compound I-67)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400734BDBM400734(US10000476, Compound I-93)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400735BDBM400735(US10000476, Compound I-94)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400736BDBM400736(US10000476, Compound I-96 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400736BDBM400736(US10000476, Compound I-96 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400730BDBM400730(US10000476, Compound I-89)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400731BDBM400731(US10000476, Compound I-90)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400732BDBM400732(US10000476, Compound I-91)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400733BDBM400733(US10000476, Compound I-92)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400726BDBM400726(US10000476, Compound I-85)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400727BDBM400727(US10000476, Compound I-86)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400728BDBM400728(US10000476, Compound I-87)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400729BDBM400729(US10000476, Compound I-88)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400722BDBM400722(US10000476, Compound I-81)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400723BDBM400723(US10000476, Compound I-130 | US10000476, Compound ...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400724BDBM400724(US10000476, Compound I-83)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400725BDBM400725(US10000476, Compound I-84)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400751BDBM400751(US10000476, Compound I-110)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400752BDBM400752(US10000476, Compound I-111)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400753BDBM400753(US10000476, Compound I-112)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400746BDBM400746(US10000476, Compound I-105)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400747BDBM400747(US10000476, Compound I-106)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400748BDBM400748(US10000476, Compound I-107)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400749BDBM400749(US10000476, Compound I-108)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400742BDBM400742(US10000476, Compound I-101)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400743BDBM400743(US10000476, Compound I-102)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 400744BDBM400744(US10000476, Compound I-103)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

Displayed 1 to 50 (of 229 total ) | Next | Last >>
Jump to: